Cell Based Assays Market Report 2026

The cell based assays market size has grown rapidly in recent years. It will grow from $29.41 billion in 2025 to $33.21 billion in 2026 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increasing drug discovery activities, expansion of in vitro research methodologies, rising use of cell-based models in basic research, availability of advanced assay consumables, growth of pharmaceutical R&D spending.

The cell based assays market size is expected to see rapid growth in the next few years. It will grow to $54.79 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing adoption of AI-assisted assay analysis, rising demand for complex disease modeling, expansion of personalized medicine research, growing use of automation in laboratories, increasing investments in advanced screening platforms. Major trends in the forecast period include increasing adoption of high-throughput cell-based screening, rising use of automated cell handling systems, growing demand for predictive toxicology assays, expansion of label-free cell analysis methods, enhanced focus on physiologically relevant cell models.

The growth in biologics sales is expected to drive the expansion of the cell-based assays market. Biologics, or biological products, refer to medicines derived from living organisms and include a range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. Cell-based assays play a crucial role in biologics for assessing functionality, potency, safety, and bio-similarity. For example, in October 2024, according to the Generics and Biosimilars Initiative, a Belgium-based organization providing high-quality scientific information on generic and biosimilar medicines, beyond the nine top-selling biologics, two additional complex drugs reported substantial sales in 2023. Novo Nordisk’s Ozempic (semaglutide) and Eli Lilly’s Trulicity (dulaglutide), both used to treat type 2 diabetes, achieved sales of US$14 billion and US$7.2 billion, respectively. Consequently, the increase in electronic payment methods is contributing to the growth of the cell-based assays market.

Major companies in the cell-based assays market are introducing new platforms leveraging technologies such as cell-based phenotypic assay platforms to provide advanced solutions for drug discovery. A cell-based phenotypic assay platform is a system used in drug discovery to evaluate cellular responses to compound treatments by combining advanced imaging and analytical tools, enhanced by artificial intelligence. For example, in June 2024, Sphere Fluidics, a UK-based life sciences R&D company, launched Cyto-Cellect PLUS. Cyto-Cellect PLUS is a user-friendly Fluorescence Resonance Energy Transfer (FRET) assay that enables researchers to measure IgG productivity with high accuracy and sensitivity. Building on Sphere Fluidics’ original Cyto-Cellect Human IgGκ Detection Kit, this upgraded version also detects both IgG κ and λ light chains, expanding its range of applications. The assay is fully compatible with existing Cyto-Mine® functionality, supporting single-cell dispensing into 96-well and 384-well plates. Moreover, it complies with relevant regulatory standards by being free of animal-derived components, allowing seamless integration into current cell line development workflows.

In April 2023, Discovery Life Sciences, a U.S.-based provider of biospecimen solutions and services, acquired ReachBio Research Labs for an undisclosed amount. Through this acquisition, Discovery Life Sciences aims to broaden its preclinical and clinical research capabilities, improve its biologics testing services, accelerate drug development timelines, and enhance its overall service offerings. ReachBio Research Labs is a U.S.-based contract research organization (CRO) that specializes in cell-based assays.

Major companies operating in the cell based assays market are Promega Corporation, Bio-Rad Laboratories Inc, PerkinElmer Inc, Abcam plc, Enzo Life Sciences Inc, Cell Signaling Technology Inc, Cisbio International LLC, Eurofins Scientific SE, Charles River Laboratories International Inc, Miltenyi Biotec GmbH, Lonza Group Ltd, Corning Incorporated, Becton Dickinson and Company, Danaher Corporation, GE HealthCare Technologies Inc, BioVision Inc, Biotium Inc, ProQinase GmbH, QGel SA, Cell Biolabs Inc.

North America was the largest region in the cell-based assays market in 2025. Western Europe was the second largest region in the global cell-based assays market share. The regions covered in the cell based assays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cell based assays market by increasing costs of imported reagents, assay kits, microplates, analytical instruments, and automated handling systems used across pharmaceutical and research laboratories. North America and Europe are most affected due to reliance on specialized imported consumables and instruments, while Asia-Pacific faces higher costs for advanced assay technologies. These tariffs are increasing operational expenses and slowing procurement cycles for research institutions. However, they are also encouraging local production of consumables, regional instrument assembly, and supply chain diversification to support long-term market stability.

The cell based assays market research report is one of a series of new reports that provides cell based assays market statistics, including cell based assays industry global market size, regional shares, competitors with a cell based assays market share, detailed cell based assays market segments, market trends and opportunities, and any further data you may need to thrive in the cell based assays industry. This cell based assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell-based assays are experimental tools designed to investigate reactions occurring within cells. These assays are utilized to examine mechanisms or processes of cellular function.

The primary products and services for cell-based assays include consumables, instruments, services, and software. Consumables are items that are used up or depleted during their use. The instruments commonly employed include microplates, microplate readers, high-throughput screening systems, and liquid handling systems. Consumables comprise reagents and media, cells and cell lines, probes, and labels. The various technology types of cell-based assays include automated handling, flow cytometry, label-free detection, high-throughput screening, and others, which are applied for drug discovery, basic research, ADME studies, predictive toxicology, and additional purposes. The different end users include pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CROs), and others.

The cell-based assay market consists of sales of reagents, cell lines, microplates, microplates, assay kits, probes, and labels. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.